Pharmacovigilance and Clinical Trials

Drug repurposing to treat Viruses: COVID-19

Tracks 16: Drug repurposing to treat Viruses: COVID-19

<p 0px="" 16:="" background-color:="" drug="" margin:="" n="" p="" repurposing="" style="" text-align:"="" text-align:="" to="" tracks="" treat="" viruses:=""> Drug repurposing is a methodology for making more value from an existing drug by targeting diseases by focusing on infections other than that for which it was initially proposed, For instance, teicoplanin, oritavancin, dalbavancin and monensin are affirmed antibiotics that have been appeared to inhibit corona- and other viruses in the research facility. The researchers reviewed information on the discovery and development of wide-spectrum antiviral agents (BSAAs), which are drugs that target viruses from two or more different viral families. They condensed what they found for 120 drugs that had just been demonstrated to be ok for people use and made a database, which is uninhibitedly available Thirty-one of these were found by the researchers to be possible candidates for prophylaxis and treatment of the COVID-19 infections. The researchers also found that clinical investigations have recently begun of five possible drug candidates to treat the virus that causes COVID-19.